GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’ July 10, 2026Posted inBiotechnology Hansoh Pharmaceutical’s pair of much-hyped ADCs continue to justify partner GSK’s decision to make them priority programs. Post navigation Previous Post Delirium Rates in German Nursing Homes Revealed in New StudyNext PostIHealthScreen nabs FDA nod for AI-backed dx to spot mild diabetic retinopathy
